ArticleDrug and alcohol dependence2026
Links between cannabinoid hyperemesis syndrome symptoms and drug use, mental health problems, antisocial behavior, and personality in a national survey of adults in the United States.
Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Links between Cannabinoid Hyperemesis Syndrome symptoms and drug use, mental health problems, antisocial behavior, and personality in a national survey of adults in the United States.medRxiv : the preprint server for health sciences · 2026Article
- Elevated suicidal thoughts and behaviors, proximal suicide risk factors, and non-suicidal self-injury among adults reporting symptoms of Cannabinoid Hyperemesis Syndrome: Results from a national survey of US adults.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCannabinoid hyperemesis syndrome (CHS) is characterized by episodes of severe nausea, vomiting, and abdominal pain among those with heavy cannabis use. We estimated differences between those reporting CHS symptoms and those who use cannabis daily and less frequently on drug use, psychiatric symptoms, other health aliments, antisocial behavior, and personality.
methodsThe National Firearms, Alcohol, Cannabis, and Suicide survey was administered to 7034 US adults (3427 male, 3607 female) in 2025. Survey items assessed substance use, common psychiatric symptoms, personality traits, and symptoms of CHS.
resultsThose with CHS symptoms reported the highest rates and greatest variety of drug use compared to others who used cannabis. Those with CHS symptoms reported higher rates of other drug use than those who used cannabis daily without CHS symptoms for opioids, hallucinogens, and sedatives, higher rates of drug overdoses, and greater use of all drug classes than those with less-than-daily cannabis use. Those with CHS symptoms also reported more depression, anxiety, sleep disturbances, chronic pain, antisocial behavior, intimate partner violence, and disinhibited personality traits than those who used cannabis daily (mean d = 0.58) and less frequently (mean d = 0.69) and those with no cannabis use in the past 12 months (mean d = 0.99).
conclusionsThose with CHS symptoms exhibit a variety of psychological and behavioral difficulties including higher rates of other drug use, psychiatric symptoms, antisocial behavior, and dysfunctional personality traits. Results highlight the importance of understanding and addressing the broader psychosocial challenges faced by people experiencing CHS symptoms.
Indexed as
Identifiers
42617216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.